PE20050337A1 - COMPUESTOS DE OXAZOL COMO INHIBIDORES DE LA PRODUCCION DEL PEPTIDO Aß - Google Patents
COMPUESTOS DE OXAZOL COMO INHIBIDORES DE LA PRODUCCION DEL PEPTIDO AßInfo
- Publication number
- PE20050337A1 PE20050337A1 PE2004000763A PE2004000763A PE20050337A1 PE 20050337 A1 PE20050337 A1 PE 20050337A1 PE 2004000763 A PE2004000763 A PE 2004000763A PE 2004000763 A PE2004000763 A PE 2004000763A PE 20050337 A1 PE20050337 A1 PE 20050337A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- alkynyl
- alkenyl
- inhibitors
- peptide production
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A DERIVADOS DE OXAZOL DE FORMULA I, INCLUYENDO SUS SALES FARMACEUTICAMENTE ACEPTABLES, EN DONDE Z ES C(=O)CHR1R2, C(=S)CHR1R2, C(=O)C(=O)R1, ENTRE OTROS; R1 ES ALQUILO C1-C20, ALQUENILO C2-C20, ALQUINILO C2-C20, ALCOXI C1-C20, ENTRE OTROS; R2 ES H, OH, NH2, CH2OH, OC(=O)CH3, C(CH3)2OH, ENTRE OTROS; R3 ES ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6 o (ALQUILEN (C0-C4)-(CICLOALQUILO C3-C6)); R5 ES H, ALQUILO C1-C4, ALQUENILO C2-C4, ALQUINILO C2-C4, C(=O)(ALQUILO(C1-C4)), ARILO C6-C10, ENTRE OTROS; R6 ES H, ALQUILO C1-C4, ALQUENILO C2-C4, F, Cl, Br, I, CN, CF3, ENTRE OTROS; R7 ES H, ALQUILO C1-C20, ALQUENILO C2-C20, ALQUINILO C2-C20, ALCOXI C1-C20, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ESTER ETILICO DEL ACIDO 2-{2-[2-(3,5-DIFLUOROFENIL)-ACETILAMINO]-BUTILAMINO}-4-TRIFLUOROMETILOXAZOL-5-CARBOXILICO; (5-BENZOILOXAZOL-2-IL)-AMIDA DEL ACIDO 2-[2-(3-FENOXIFENIL)-ACETILAMINO]-PENTANOICO; (5-ACETILOXAZOL-2-IL)-AMIDA DEL ACIDO 2-[2-(3-FENOXIFENIL)-ACETILAMINO]-PENTANOICO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DE LA PRODUCCION DEL PEPTIDO Aß Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS NEURODEGENERATIVOS Y/O NEUROLOGICOS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49288403P | 2003-08-06 | 2003-08-06 | |
| US49802803P | 2003-08-27 | 2003-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20050337A1 true PE20050337A1 (es) | 2005-06-06 |
Family
ID=34197958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2004000763A PE20050337A1 (es) | 2003-08-06 | 2004-08-06 | COMPUESTOS DE OXAZOL COMO INHIBIDORES DE LA PRODUCCION DEL PEPTIDO Aß |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7112599B2 (es) |
| EP (1) | EP1653952A4 (es) |
| JP (1) | JP2007501244A (es) |
| AR (1) | AR046327A1 (es) |
| BR (1) | BRPI0413349A (es) |
| CA (1) | CA2534529A1 (es) |
| MX (1) | MXPA06001480A (es) |
| PA (1) | PA8608601A1 (es) |
| PE (1) | PE20050337A1 (es) |
| SV (1) | SV2005001840A (es) |
| TW (1) | TW200510351A (es) |
| UY (1) | UY28458A1 (es) |
| WO (1) | WO2005016267A2 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20084420B (en) * | 2004-03-23 | 2008-07-10 | Pfizer Prod Inc | Use of imidazole compounds for the treatment of neurodegenerative disorders |
| US20050222227A1 (en) * | 2004-04-01 | 2005-10-06 | Pfizer Inc | Oxazole-amine compounds for the treatment of neurodegenerative disorders |
| KR20080040010A (ko) * | 2005-09-22 | 2008-05-07 | 화이자 프로덕츠 인코포레이티드 | 신경계 질환 치료용 이미다졸 화합물 |
| WO2008098857A1 (en) | 2007-02-15 | 2008-08-21 | F. Hoffmann-La Roche Ag | 2-aminooxazolines as taar1 ligands |
| JP5053459B2 (ja) | 2009-01-12 | 2012-10-17 | アイカジェン， インコーポレイテッド | スルホンアミド誘導体 |
| AU2013270036B2 (en) | 2012-05-31 | 2016-12-01 | Phenex Pharmaceuticals Ag | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR(gamma) |
| MA52092A (fr) * | 2018-03-23 | 2021-01-27 | Yumanity Therapeutics Inc | Composés et leurs utilisations |
| CN113651805B (zh) * | 2021-07-19 | 2023-07-25 | 安徽医科大学 | 一种1,2,4-噁二唑-吡啶类化合物及其在治疗阿尔茨海默症中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3094462A (en) * | 1961-09-18 | 1963-06-18 | Mcneilab Inc | Therapeutic reaction complex for muscle relaxation |
| US3591584A (en) * | 1968-08-27 | 1971-07-06 | Pfizer | Benzothiazine dioxides |
| GB1264258A (es) * | 1970-10-10 | 1972-02-16 | ||
| GB9320660D0 (en) * | 1993-10-07 | 1993-11-24 | British Bio Technology | Inhibition of cytokine production |
| US6169102B1 (en) * | 1996-06-25 | 2001-01-02 | Takeda Chemical Industries, Ltd. | Oxazolone derivatives and their use as anti-Helicobacter pylori agent |
| US20020002199A1 (en) * | 1998-03-12 | 2002-01-03 | Lone Jeppesen | Modulators of protein tyrosine phosphatases (ptpases) |
| WO2000059285A2 (en) * | 1999-04-02 | 2000-10-12 | Du Pont Pharmaceuticals Company | NOVEL LACTAM INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE |
| TW593241B (en) * | 1999-04-20 | 2004-06-21 | Hoffmann La Roche | Carbamic acid derivatives |
| AR039059A1 (es) * | 2001-08-06 | 2005-02-09 | Sanofi Aventis | Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios |
| EP1551815A1 (en) * | 2002-10-09 | 2005-07-13 | Pfizer Products Inc. | Thiazole compounds for the treatment of neurodegenerative disorders |
| CA2501799C (en) * | 2002-10-09 | 2008-06-17 | Pfizer Products Inc. | Pyrazole compounds for treatment of neurodegenerative disorders |
| CA2511337C (en) * | 2002-12-23 | 2011-12-20 | F.Hoffmann-La Roche Ag | Oxazoles as mglur1 enhancer |
| BRPI0406747A (pt) * | 2003-01-13 | 2005-12-20 | Hoffmann La Roche | Derivados de benzoxazol e seu uso como ligandos de receptor de adenosina |
-
2004
- 2004-08-04 CA CA002534529A patent/CA2534529A1/en not_active Abandoned
- 2004-08-04 BR BRPI0413349-8A patent/BRPI0413349A/pt not_active IP Right Cessation
- 2004-08-04 WO PCT/US2004/025023 patent/WO2005016267A2/en active Application Filing
- 2004-08-04 JP JP2006522669A patent/JP2007501244A/ja not_active Withdrawn
- 2004-08-04 MX MXPA06001480A patent/MXPA06001480A/es active IP Right Grant
- 2004-08-04 EP EP04779943A patent/EP1653952A4/en not_active Withdrawn
- 2004-08-05 TW TW093123538A patent/TW200510351A/zh unknown
- 2004-08-05 US US10/911,869 patent/US7112599B2/en not_active Expired - Fee Related
- 2004-08-06 AR ARP040102804A patent/AR046327A1/es unknown
- 2004-08-06 UY UY28458A patent/UY28458A1/es not_active Application Discontinuation
- 2004-08-06 PA PA20048608601A patent/PA8608601A1/es unknown
- 2004-08-06 PE PE2004000763A patent/PE20050337A1/es not_active Application Discontinuation
- 2004-08-09 SV SV2004001840A patent/SV2005001840A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0413349A (pt) | 2006-10-10 |
| WO2005016267A2 (en) | 2005-02-24 |
| PA8608601A1 (es) | 2005-03-03 |
| EP1653952A2 (en) | 2006-05-10 |
| JP2007501244A (ja) | 2007-01-25 |
| SV2005001840A (es) | 2005-11-04 |
| UY28458A1 (es) | 2005-03-31 |
| MXPA06001480A (es) | 2006-05-15 |
| TW200510351A (en) | 2005-03-16 |
| EP1653952A4 (en) | 2007-04-04 |
| US20050032859A1 (en) | 2005-02-10 |
| WO2005016267A3 (en) | 2005-04-21 |
| US7112599B2 (en) | 2006-09-26 |
| AR046327A1 (es) | 2005-12-07 |
| CA2534529A1 (en) | 2005-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20051155A1 (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos | |
| AU2007311087B2 (en) | Organic compounds | |
| RU2361870C2 (ru) | Новые кумарины, их карбоксамидные производные, способы получения, композиции и применение | |
| PE20040155A1 (es) | Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen | |
| PE20040650A1 (es) | Moduladores del receptor de glucocorticoides | |
| PE20030856A1 (es) | Esteres hidroxamato del acido n-(4-fenilsustituido)-antranilico | |
| PE20060589A1 (es) | FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b | |
| PE20061305A1 (es) | Compuestos derivados de fenilacetamidas como inhibidores de proteincinasas | |
| CO5700757A2 (es) | Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
| PE20061290A1 (es) | Derivados de 1-benzil-indol-2-carboxamida | |
| PE20040640A1 (es) | Compuestos de tiazol como inhibidores de la enzima gamma secretasa | |
| PE20090813A1 (es) | Inhibidores de la 11b-hidroxiesteroide-deshidrogenasa | |
| PE20061106A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| PE20040898A1 (es) | Nuevos compuestos derivados de pirimidina | |
| CA2536136A1 (en) | Aryloxy and arylalkyleneoxy substituted imidazoquinolines | |
| ES2314418T3 (es) | Derivados de amidas del acido 4-bromo-5-(2-clorobenzoilamino)-1h-pirazol-3-carboxicilico y compuestos relacionados como antagonistas del receptor b1 de bradiquinina para el tratamiento de enfermedades inflamatorias. | |
| SE9702799D0 (sv) | New compounds | |
| PE20130149A1 (es) | Derivados de la cromenona con actividad anti-tumoral | |
| RU2010120682A (ru) | Ингибиторы гистондезацетилазы | |
| PE20030925A1 (es) | Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico | |
| PE20071132A1 (es) | Compuestos macrociclicos como inhibidores del factor viia | |
| PE20040911A1 (es) | Derivados de 3h-quinazolin-4-ona como inhibidores selectivos de la monoaminooxidasa b | |
| PE20050337A1 (es) | COMPUESTOS DE OXAZOL COMO INHIBIDORES DE LA PRODUCCION DEL PEPTIDO Aß | |
| NO20064951L (no) | 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse | |
| PE20061155A1 (es) | Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |